-+ 0.00%
-+ 0.00%
-+ 0.00%

Climb Bio presents initial Phase 1 data for CLYM116 in healthy volunteers at ERA 2026

PUBT·05/26/2026 11:05:35
Listen to the news
Climb Bio presents initial Phase 1 data for CLYM116 in healthy volunteers at ERA 2026
  • Climb Bio flagged upcoming data presentations at the European Renal Association Congress in Glasgow on June 3-6, 2026.
  • Initial Phase 1 safety findings for CLYM116 in healthy volunteers will be presented on June 5.
  • PK/PD modeling for CLYM116 to support development in IgA nephropathy will also be presented at the meeting.
  • A trial-in-progress update will outline PrisMN, an ongoing Phase 2 study of budoprutug in primary membranous nephropathy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260700PRIMZONEFULLFEED9726202) on May 26, 2026, and is solely responsible for the information contained therein.